Clinical Trial Update: A Study of Gefitinib With or Without Apatinib in Patients With Advanced Non-squamous Non-Small-Cell Lung Cancer Harboring EGFR Mutations [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial update studying gefitinib with or without apatinib in advanced non-squamous non-small cell lung cancer harboring EGFR mutations.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Apatinib (apatinib)
• Iressa (gefitinib)

Snippet

Sponsor: Sun Yat-sen University | Conditions: EGFR Tyrosine Kinase Inhibitors Plus VEGFR Inhibitors | Phase 3 | Status: UNKNOWN